Yesterday, the US Food & Drug Administration (FDA) did something it has never done before. It approved a drug for the treatment of a type of cancer based exclusively on the presence of a specific biomarker — with no reference to the location of the cancer in the patient’s body. … READ MORE …
Filed under: Drugs in development | Tagged: approval, biomarker, FDA, pembrolizumab | 8 Comments »
Nearly a year ago now, the American Society of Clinical Oncology (ASCO) first announced plans to initiate an innovative trial of a personalized medicine initiative called the Targeted Agent and Profiling Utilization Registry (TAPUR) study. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, biomarker, genomic, medicine, personalized, TAPUR, Treatment, trial | 3 Comments »
Both Myriad Genetics and Genome DX Biosciences issued media releases today stating that Medicare contractors have issued draft coverage recommendations for tests used to assess the aggressiveness of prostate cancer based on genetic/genomic analyses of tissue from biopsy and post-surgical samples. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biomarker, Decipher, genetic, genomic, PROLARIS, risk, test | Leave a comment »
An article just published on line in Clinical Cancer Research supposedly reports the discovery of a single nucleotide polymorphism or SNP that may be useful in predicting which patients with Gleason 7 disease are most likely to have a more aggressive form of cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressiveness, biomarker, Gleason, grade, KLK3, nucleotide, polymorphism, single, SNP | 1 Comment »
It has been brought to our attention by one of our readers that a Swedish company called AroCell is developing a new test that may have potential in monitoring for risk of prostate cancer progression. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: biomarker, kinase, progression, risk, thymidine | 11 Comments »
A new study just published on line in Clinical Cancer Research shows a degree of correlation between the results of tests for PCA3 and the TMRPSS2-ERG biomarker and risk for progressive disease in men on active surveillance. However, this correlation appears to be less than compelling. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: acgtive surveillance, biomarker, PCA3, risk, TMRPSS2-ERG | Leave a comment »
A newly published article, available on-line in the journal Prostate Cancer and Prostatic Diseases, shows that tissues from prostate biopsies from black men express higher levels of biomarkers for aggressive disease than do tissues from prostate biopsies taken from white men. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: aggressive, biomarker, black, risk, white | Leave a comment »
There is increasing concurrence that the addition of GEMCaP biomarker data may be able to improve the prognostic accuracy of the Kattan post-treatment nomogram. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: biomarker, GEMCaP, Kattan, nomogram, post-surgical, prognosis | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 